Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|21|26|3813-3828

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.26, 2015-01, pp. : 3813-3828

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New phosphodiesterase inhibitors in the treatment of erectile dysfunction

By Anderson Paul CB   Gommersall Lyndon   Hayne Dickon   Arya Manit   Patel Hitendra RH  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2241-2249

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

By  

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite

GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia

By  

Current Neuropharmacology, Vol. 3, Iss. 1, 2005-01 ,pp. : 45-62

Bentham Science Publishers

Access to resources Recommend Favorite

5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia

By  

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3739-3759

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite